Imara Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $34.5M

Imara General Information

Description

Developer of novel therapeutics designed to treat patients with sickle cell disease and other hemoglobinopathies. The company is focused on developing and commercializing novel therapeutics to treat patients with rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases, and on its product candidate, tovinontrine (IMR-687), enabling people to get a cure for their illness.

Contact Information

Website
www.imaratx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 116 Huntington Avenue
  • 6th Floor
  • Boston, MA 02116
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 116 Huntington Avenue
  • 6th Floor
  • Boston, MA 02116
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imara Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 23-Feb-2023 $34.5M Completed Profitable
4. IPO 12-Mar-2020 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 01-Feb-2020 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 14-Apr-2016 $31M $34M Completed Clinical Trials - Phase 1
1. Seed Round 26-Jan-2016 $3M $3M Completed Clinical Trials - Phase 1
To view Imara’s complete valuation and funding history, request access »

Imara Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 2,712,960 $0.001000 8% $1 $1 1x $1 2.73%
To view Imara’s complete cap table history, request access »

Imara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to treat patients with sickle cell disease and other hemoglobinopathies. The co
Drug Discovery
Boston, MA
6 As of 2022

Plymouth Meeting, PA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Imara Competitors (80)

One of Imara’s 80 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Prevail Therapeutics Formerly VC-backed New York, NY
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Immunitas Therapeutics Formerly VC-backed Boston, MA
Taysha Gene Therapies Formerly VC-backed Dallas, TX
You’re viewing 5 of 80 competitors. Get the full list »

Imara Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imara Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Arix Bioscience Venture Capital Minority
Bay City Capital Venture Capital Minority
Lundbeckfonden BioCapital Venture Capital Minority
NB Ventures Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Imara Investments & Acquisitions (3)

Imara’s most recent deal was a Reverse Merger with Enliven Therapeutics for . The deal was made on 23-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Enliven Therapeutics 23-Feb-2023 Reverse Merger Drug Discovery
Complexa (Activator of Nuclear Factor Erythroid 2-Related Factor 2 Drug) 01-Oct-2020 Corporate Asset Purchase Buildings and Property
Lundbeck (Exclusive Worldwide License To IMR-687, A Hemoglobinopathy Drug) 16-Apr-2016 Corporate Asset Purchase Buildings and Property
To view Imara’s complete investments and acquisitions history, request access »

Imara ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Imara’s complete esg history, request access »

Imara FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process